AzurRx BioPharma, Inc. (NASDAQ: AZRX), the stock was trending lower -16.4% to $1.65 in the pre-opening session.AZRX stock’s performance has improved over the past few months, evident in Tuesday’s stock price gain. Using several metrics, we can gauge the stock’s performance this year. In the 52 weeks ending today, the high price of AZRX was $2.63, which is 24.33 percent higher than the stock’s current price. However, the current price of AZRX is higher than its 52-week low of $0.37.
Two additional new sites in Poland have been activated for the Expansion arm of Phase 2b OPTION 2 study investigating immediate-release capsules of MS1819 to treat exocrine pancreatic insufficiency in patients with cystic fibrosis (CF).
- 3 Best Gene Therapy Stocks for long-term Investment
- Two of the Best Pharmaceutical Stocks to Watch for in 2021
During the ongoing COVID-19 pandemic, additional sites were added across Europe to minimize any possible patient enrollment delays. In Poland and the United States, active clinical trial sites are enrolling patients, and the Company expects to report topline data in the first quarter of 2021.
The OPTION 2 clinical trial is a Phase 2b open-label crossover study designed to explore the safety, tolerability, and efficacy of MS1819 vis-à-vis the current standard of care, porcine pancreatic enzyme replacement therapy pills. Primary efficacy endpoints include the coefficient of fat absorption (CFA).
MS1819 will be tested with immediate-release capsules in OPTION 2 Phase 2b trial to find out what the optimal dose and delivery method for MS1819 should be. Patients 18 years of age or older will be included in the extension arm if they have completed OPTION 2 crossover at a higher dose level than OPTION 1. Newly dosed expansion arm participants will be treated for two weeks.
If someone is considering buying this stock, you should take note that analysts at four brokerage firms rate AzurRxBioPharma Inc. (AZRX) at a consensus value of 2.20. Precisely, 3 of the Wall Street analysts polled rate the stock as a buy, the other 1 believes investors should hold the stock, and no analyst gives the stock a “Sell.”